A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 2, 2015, Pages 227-235

  Amar, Marcelo J A ^a,b   Sakurai, Toshihiro ^a   Sakurai Ikuta, Akiko ^a   Sviridov, Denis ^a   Freeman, Lita ^a   Ahsan, Lusana ^a   Remaley, Alan T ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5A PEPTIDE; ABC TRANSPORTER A1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C2 MIMETIC PEPTIDE; APOLIPOPROTEIN E; CHOLESTEROL; LIPOPROTEIN LIPASE; PEPTIDE; PEPTIDOMIMETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; C-II-A PEPTIDE; LIPOPROTEIN LIPASE ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BHK CELL LINE; C57BL 6 MOUSE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSFECTION; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; KNOCKOUT MOUSE; LIPOLYSIS; LIPOPROTEIN DEFICIENCY; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN STRUCTURE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; CIRCULAR DICHROISM; DRUG DESIGN; DRUG EFFECTS; GENETICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; METABOLISM;

ANIMALS; APOLIPOPROTEINS E; CHOLESTEROL; CIRCULAR DICHROISM; DRUG DESIGN; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; HYPERTRIGLYCERIDEMIA; IN VITRO TECHNIQUES; LIPOLYSIS; LIPOPROTEIN LIPASE; LIPOPROTEIN LIPASE ACTIVATORS; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, MOLECULAR; PEPTIDES; TRIGLYCERIDES;

EID: 84919740443     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.220418     Document Type: Article

References (46)

1. Amar MJ, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, Sviridov D, et al. (2010) 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther 334:634-641.
2. Amar MJ, Dugi KA, Haudenschild CC, Shamburek RD, Foger B, ChaseM, Bensadoun A, Hoyt RF, Jr, Brewer HB, Jr, and Santamarina-Fojo S (1998) Hepatic lipase facilitates the selective uptake of cholesteryl esters from remnant lipoproteins in apoE-deficient mice. J Lipid Res 39:2436-2442.
3. Anantharamaiah GM, Jones JL, Brouillette CG, Schmidt CF, Chung BH, Hughes TA, Bhown AS, and Segrest JP (1985) Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem 260:10248-10255.
4. Anderson F, Thomson SR, Clarke DL, and Buccimazza I (2009) Dyslipidaemic pancreatitis clinical assessment and analysis of disease severity and outcomes. Pancreatology 9:252-257.
5. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, and Stalenhoef AF (2012) Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:2969-2989.
6. Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, and Azhar S (2010) A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 51:1496-1503.
7. Carballo-Jane E, Chen Z, O'Neill E, Wang J, Burton C, Chang CH, Chen X, Eveland S, Frantz-Wattley B, Gagen K, et al. (2010) ApoA-I mimetic peptides promote pre-b HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose. Bioorg Med Chem 18:8669-8678.
8. Connelly PW, Maguire GF, Hofmann T, and Little JA (1987) Structure of apolipoprotein C-IIToronto, a nonfunctional human apolipoprotein. Proc Natl Acad Sci USA 84:270-273.
9. Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, Lu Y, Tang ZZ, Zhang H, Hindy G, et al.; TG and HDL Working Group of the Exome Sequencing Project; National Heart, Lung, and Blood Institute (2014) Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371:22-31.
10. Dai C, Yao X, Keeran KJ, Zywicke GJ, Qu X, Yu ZX, Dagur PK, McCoy JP, Remaley AT, and Levine SJ (2012) Apolipoprotein A-I attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony-stimulating factordependent mechanism. Am J Respir Cell Mol Biol 47:186-195.
11. Dominguez-Munoz JE, Malfertheiner P, Ditschuneit HH, Blanco-Chavez J, Uhl W, Buchler M, and Ditschuneit H (1991) Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. Int J Pancreatol 10: 261-267.
12. Fojo SS and Brewer HB (1992) Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med 231:669-677.
13. Fruchart-Najib J, Baugé E, Niculescu LS, Pham T, Thomas B, Rommens C, Majd Z, Brewer B, Pennacchio LA, and Fruchart JC (2004) Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 319:397-404.
14. González-Navarro H, Nong Z, Amar MJ, Shamburek RD, Najib-Fruchart J, Paigen BJ, Brewer HB, Jr, and Santamarina-Fojo S (2004) The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice. J Biol Chem 279:45312-45321.
15. Gordon SM and Davidson WS (2012) Apolipoprotein A-I mimetics and high-density lipoprotein function. Curr Opin Endocrinol Diabetes Obes 19:109-114.
16. Graham MJ, Lee RG, Bell TA, 3rd, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J, et al. (2013) Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 112:1479-1490.
17. Jong MC, Hofker MH, and Havekes LM (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19:472-484.
18. Kei AA, Filippatos TD, Tsimihodimos V, and Elisaf MS (2012) A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 61:906-921.
19. Kersten S (2014) Physiological regulation of lipoprotein lipase. Biochim Biophys Acta 1841:919-933.
20. Krause BR and Remaley AT (2013) Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol 24:480-486.
21. Leman LJ, Maryanoff BE, and Ghadiri MR (2014) Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J Med Chem 57: 2169-2196.
22. Lomize AL, Pogozheva ID, Lomize MA, and Mosberg HI (2006) Positioning of proteins in membranes: a computational approach. Protein Sci 15 :1318-1333.
23. Melegh BI, Duga B, Sümegi K, Kisfali P, Maász A, Komlósi K, Hadzsiev K, Komoly S, Kosztolányi G, and Melegh B (2012) Mutations of the apolipoprotein A5 gene with inherited hypertriglyceridaemia: review of the current literature. Curr Med Chem 19 :6163-6170.
24. Musliner TA, Herbert PN, and Church EC (1979) Activation of lipoprotein lipase by native and acylated peptides of apolipoprotein C-II. Biochim Biophys Acta 573: 501-509.
25. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, Li X, Li H, Kuperwasser N, Ruda VM, et al. (2010) From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466:714-719.
26. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE, Carson ER, Morgenthaler JJ, Lerch P, and Miller NE (1996) Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol 16:1203-1214.
27. Nanjee MN, Doran JE, Lerch PG, and Miller NE (1999) Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol 19:979-989.
28. Navab M, Shechter I, Anantharamaiah GM, Reddy ST, Van Lenten BJ, and Fogelman AM (2010) Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 30:164-168.
29. Olivecrona G and Beisiegel U (1997) Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CII-deficient chylomicrons. Arterioscler Thromb Vasc Biol 17:1545-1549.
30. Ooi EM, Barrett PH, Chan DC, and Watts GF (2008) Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 114: 611-624.
31. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, et al. (2008) A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322:1702-1705.
32. Remaley AT, Amar M, and Sviridov D (2008) HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther 6:1203-1215.
33. Remaley AT, Thomas F, Stonik JA, Demosky SJ, Bark SE, Neufeld EB, Bocharov AV, Vishnyakova TG, Patterson AP, Eggerman TL, et al. (2003) Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 44:828-836.
34. Sankaranarayanan S, Oram JF, Asztalos BF, Vaughan AM, Lund-Katz S, Adorni MP, Phillips MC, and Rothblat GH (2009) Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J Lipid Res 50: 275-284.
35. Sethi AA, Amar M, Shamburek RD, and Remaley AT (2007) Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs 8:201-212.
36. Sethi AA, Stonik JA, Thomas F, Demosky SJ, Amar M, Neufeld E, Brewer HB, Davidson WS, D'Souza W, Sviridov D, et al. (2008) Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem 283:32273-32282.
37. Shachter NS, Hayek T, Leff T, Smith JD, Rosenberg DW, Walsh A, Ramakrishnan R, Goldberg IJ, Ginsberg HN, and Breslow JL (1994) Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest 93:1683-1690.
38. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, Woollard K, Lyon S, Sviridov D, and Dart AM (2008) Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 103:1084-1091.
39. Shen Y, Lookene A, Nilsson S, and Olivecrona G (2002) Functional analyses of human apolipoprotein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase. J Biol Chem 277:4334-4342.
40. Tabet F, Remaley AT, Segaliny AI, Millet J, Yan L, Nakhla S, Barter PJ, Rye KA, and Lambert G (2010) The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 30:246-252.
41. Thévenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, and Tufféry P (2012) PEPFOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res 40:W288-W293.
42. Tsuang W, Navaneethan U, Ruiz L, Palascak JB, and Gelrud A (2009) Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol 104:984-991.
43. Vaughan AM and Oram JF (2003) ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res 44:1373-1380.
44. Viljoen A and Wierzbicki AS (2012) Diagnosis and treatment of severe hypertriglyceridemia. Expert Rev Cardiovasc Ther 10:505-514.
45. Wang CS, McConathy WJ, Kloer HU, and Alaupovic P (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75:384-390.
46. Zdunek J, Martinez GV, Schleucher J, Lycksell PO, Yin Y, Nilsson S, Shen Y, Olivecrona G, and Wijmenga S (2003) Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase. Biochemistry 42:1872-1889.